Alnylam Can Survive Being ‘Punched in the Face,’ President Says

  • Company’s value nearly halved after shuttering drug trial
  • Alnylam confident in safety of other products in testing

Alnylam Pharmaceuticals Inc. is ready to soldier on with other projects after the news that it’s shutting down a key therapy program cut its market value by almost half in a day.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.